Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799812 · ClinicalTrials.gov registry record · Phase 3
Test for Pre Operative Skin Preparations
A Phase 3 study of Topical Antisepsis, sponsored by C. R. Bard.
- Completed
- Registry status
- Phase 3
- Development phase
- 335
- Enrollment target
- 1
- Study location
NCT00799812: Completed Phase 3 study of Topical Antisepsis, sponsored by C. R. Bard.
NCT00799812 is a Phase 3 study of Topical Antisepsis that has completed, run by C. R. Bard. The registered enrollment target is 335 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00799812, a Phase 3 study of Topical Antisepsis, has completed, sponsored by C. R. Bard.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 335 participants
- Enrollment target
- 1
- Study location
Study Summary
Compare 2 application techniques of ChloraPrep Swabstick--3 swabsticks at once versus 3 swabsticks used sequentially. Hibiclens applied according to the manufacturer's directions. Sterile swabsticks (wetted with sterile deionizd water) applied using the same method as the ChloraPrep Swabstick.
Primary Outcome
The bacterial reductions achieved by the test products and the controls using 2 different application techniques at 10-minute and 6-hour sampling intervals for both groin and abdominal sites were evaluated.
Conditions Studied
Interventions
- DRUG CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once).
- DRUG CHG 2% w/v & IPA 70% v/v swab applied sequentially
- DRUG Aqueous CHG 4% w/v applied according to mfr's directions
- OTHER Sterile swabstick with sterile water (3 @ once)
- OTHER Sterile swabstick with sterile water (one-at-a-time)
Study Locations (1)
Virginia
- Microbiotest - Sterling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2007-11-13 |
| Est. Completion | 2008-06-19 |
| Phase | Phase 3 |
What the finished NCT00799812 record still lists
NCT00799812 is an interventional study that assigns participants to a tested intervention. The registered 335 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Topical Antisepsis appearing as the primary indexed condition, and to 5 interventions - of which CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once). is the first listed.
NCT00799812 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT00799812 about?
NCT00799812 is a clinical study titled "Test for Pre Operative Skin Preparations". Compare 2 application techniques of ChloraPrep Swabstick--3 swabsticks at once versus 3 swabsticks used sequentially. Hibiclens applied according to the manufacturer's directions. Sterile swabsticks (wetted with sterile deionizd water) applied using the same method as the ChloraPrep Swabstick.
What is the current status of trial NCT00799812?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 335 participants. The study started on 2007-11-13. Estimated completion is 2008-06-19.
What conditions does trial NCT00799812 study?
This clinical trial studies the following conditions: Topical Antisepsis.
What interventions are being tested in trial NCT00799812?
The interventions under investigation include: CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once). (DRUG), CHG 2% w/v & IPA 70% v/v swab applied sequentially (DRUG), Aqueous CHG 4% w/v applied according to mfr's directions (DRUG), Sterile swabstick with sterile water (3 @ once) (OTHER), Sterile swabstick with sterile water (one-at-a-time) (OTHER).
Who is sponsoring clinical trial NCT00799812?
This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00799812 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00799812's enrollment target sits among peer trials
335 1061st of 2000 higher than 940 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04134754 · 335 participants · NA
Carbon Dioxide (CO2) Chemosensitivity and SUDEP
- NCT05554406 · 335 participants · Phase 2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- NCT06183437 · 335 participants · Phase 4
The STOP-MED CTRCD Trial
- NCT06885177 · 335 participants · NA
TECTONIC CAD IVL IDE Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI